Alimera Sciences Stock
Alimera Sciences Stock
Currently there is a rather positive sentiment for Alimera Sciences with 3 Buy predictions and 0 Sell predictions.
As a result the target price of 6 € shows a positive potential of 45.72% compared to the current price of 4.12 € for Alimera Sciences.
Pros and Cons of Alimera Sciences in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alimera Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alimera Sciences | - | - | - | - | - | - | - |
| Gritstone Oncology Inc | 7.500% | 11.232% | -68.154% | -65.271% | -58.692% | -90.436% | - |
| Avid Bioservices Inc | 3.170% | 9.244% | 1.563% | -61.310% | 6.557% | -63.068% | 49.683% |
| Pacira Pharmaceuticals | -0.840% | -2.479% | -8.527% | -39.487% | -20.805% | -53.725% | -32.935% |
Comments
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at Alliance Global Partners from a "neutral" rating to a "buy" rating.
Show more
Ratings data for ALIM provided by MarketBeat